Abbildung 10: EUROPA-Studie - Perindopril
EUROPA is investigators led study, where perindopril 8 mg once daily is the ACEI of choice due to its actions ideally suitable for investigating this hypothesis. Looking more specifically at the main reasons why perindopril was chosen for the EUROPA trial, the following properties came under consideration: - Reliable 24-hour efficacy in BP reduction following a single tablet daily taken in the morning (as confirmed by its high TPR), with exceptional hemodynamic tolerance, proven when initiated and maintained in all patient types (in heart failure, post MI, as well as in patients with a history of stroke). - High tissue affinity. - Unique increase of bradykinin. - Its anti-ischemic properties proven to: - correct coronary endothelial dysfunction, - normalize the structure of resistance arteries, - normalize fibrinolitic balance and structure of resistance arteries. - Anti atherosclerotic effect - Anti ischemic efficacy - Good tolerance even in fragile patients with previous heart failure and strokes.